Functional characteristics of a modified immunoglobulin preparation for intravenous administration: Summary of studies of opsonic and protective activity against group B streptococci

1982 ◽  
Vol 2 (S2) ◽  
pp. 31S-35S ◽  
Author(s):  
Gerald W. Fischer ◽  
Samuel R. Wilson ◽  
Kenneth W. Hunter
1991 ◽  
Vol 163 (4) ◽  
pp. 792-798 ◽  
Author(s):  
H. R. Hill ◽  
L. A. Gonzales ◽  
W. A. Knappe ◽  
G. W. Fischer ◽  
D. K. Kelsey ◽  
...  

2020 ◽  
Vol 20 (3) ◽  
pp. 33-42
Author(s):  
E. A. Stepanova ◽  
I. N. Isakova-Sivak ◽  
V. A. Matyushenko ◽  
A. S. Matushkina ◽  
T. A. Smolonogina ◽  
...  

Group B streptococci (GBS) cause a number of serious diseases in humans. The development of an effective vaccine against GBS requires special approaches. In the present study, three recombinant influenza viruses were constructed on the backbone of H7N9 live attenuated influenza vaccine (LAIV) strain expressing fragments of the ScaAB lipoprotein of Streptococcus agalactiae, fused to the surface protein of the virus, hemagglutinin, using a flexible linker. Recombinant viruses with ScaAB inserts of 85, 141, and 200 amino acids were successfully rescued by the means of reverse genetics. The recombinant strains were able to grow in developing chicken embryos and MDCK cells and retained the temperature-sensitive phenotype attributable to the LAIV viruses. Studies of immunogenicity and protective activity of the vaccine candidates in BALB/c mice revealed that the most promising strain was a strain with an insert of 141 amino acids: this variant had optimal immunogenicity against influenza and GBS and had a protective effect against both pathogens. These data indicate that further studies of the recombinant vectored vaccine H7-ScaAB-141 as a combined viral-bacterial vaccine capable of protection against both influenza virus and bacterial infections caused by group B streptococci are warranted.


1984 ◽  
Vol 143 (2) ◽  
pp. 123-127 ◽  
Author(s):  
K. K. Christensen ◽  
P. Christensen ◽  
H. U. Bucher ◽  
G. Duc ◽  
C. H. Kind ◽  
...  

1985 ◽  
Vol 17 (2) ◽  
pp. 191-193
Author(s):  
Chris Mulder ◽  
Pieter Bol ◽  
Arjan Nabbe ◽  
Bob Zanen

1999 ◽  
Vol 86 (1) ◽  
pp. 61-65 ◽  
Author(s):  
Richard M. Whitehurst ◽  
Rachel Laskey ◽  
Ronald N. Goldberg ◽  
Donald Herbert ◽  
Cornelius Van Breemen

To study whether a sepsis-induced increase in des-Arg9-bradykinin (des-Arg9-BK) and bradykinin (BK) B1-receptor activity participates in the observed increase in pulmonary vascular resistance in neonatal group B streptococcal sepsis (GBS), isometric force bioassays of pulmonary artery (PA) rings were studied, after 4-h exposure to either Krebs or GBS, by using the following protocols: 1) BK dose-response curve, 2) vascular response to BK with N G-nitro-l-arginine methyl ester (l-NAME), and 3) response to des-Arg9-BK (BK metabolite and B1 agonist). PA rings exposed to BK resulted in contraction in the GBS group and a decrease in resting tension in the Control group ( P = 0.034) at a concentration of 10−5 M. GBS-treated PA rings contracted more to des-Arg9-BK than did Controls ( P < 0.001). BK (10−6 M) relaxed preconstricted PA rings incubated in GBS less than BK relaxed Controls ( P < 0.001), and preincubation withl-NAME decreased relaxation in both. These results suggest that GBS decreased endothelium-dependent BK relaxation and increased contractile response to des-Arg9-BK. We speculate that this occurs secondary to upregulation of B1 receptors reflected by B1-agonist-mediated PA contraction.


Sign in / Sign up

Export Citation Format

Share Document